Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Summary

This phase III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving chemoradiation with or without atezolizumab may work better in treating patients with limited stage small cell lung cancer.

Timeline

Start

2019-07-26

Primary completion

2024-04-21

Completion

2029-02-21

Publications

• Higgins KA, Hu C, Ross HJ, Jabbour SK, Kozono DE, Owonikoko TK, Ritter TA, Williams TM, Welsh J, Simko JP, Movsas B, Xiao C, Kaira K, Gupta AK, Mohindra P, Dib EG, Brownstein J, Chun S, Kuzma CS, Kotecha R, Onitilo AA, Chen Y, Stinchcombe TE, Wang X, Paulus R, Bradley JD. Chemoradiation +/- Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005. J Clin Oncol. 2026 Mar 10;44(8):630-640. doi: 10.1200/JCO-25-01569. Epub 2026 Jan 13.
• Higgins KA, Thomas A, Soto N, Paulus R, George TJ, Julian TB, Hartson Stine S, Markham MJ, Werner-Wasik M. Creating and Implementing a Principal Investigator Tool Kit for Enhancing Accrual to Late Phase Clinical Trials: Development and Usability Study. JMIR Cancer. 2022 Aug 25;8(3):e38514. doi: 10.2196/38514.

Drugs

Indications